ESC Premium Access

De-escalation/discontinuation of oxygen-therapy and medication is feasible and safe in chronic thromboembolic pulmonary hypertension patients treated with balloon pulmonary angioplasty

Congress Presentation

About the speaker

Doctor Mai Kimura

Keio University Hospital, Tokyo (Japan)
0 follower

2 more presentations in this session

Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study)

Speaker: Doctor E. Klok (Leiden, NL)

Thumbnail

Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects

Speaker: Mrs F. Petit Dop (Suresnes, FR)

Thumbnail

Access the full session

Advances in Chronic Thromboembolic Pulmonary Hypertension

Speakers: Doctor M. Kimura, Doctor E. Klok, Mrs F. Petit Dop
Thumbnail

About the event

Image

ESC CONGRESS 2020 - The Digital Experience

28 August - 1 September 2020

Sessions Presentations

Related content

ESC Premium Access

SGLT2 inhibitors in heart failure: adjusting other treatments and what to tell the patient.

30 August 2021

ESC Premium Access

SGLT2 inhibitors in heart failure: do I have to worry about the kidneys?

30 August 2021

ESC Premium Access

Who should be treated with an SGLT2 inhibitor?

30 August 2021

ESC 365 is supported by

logo Novo Nordisk